Christian la FougÃ¨re

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1206044/publications.pdf

Version: 2024-02-01

204 papers	9,600 citations	44069 48 h-index	49909 87 g-index
224 all docs	224 docs citations	224 times ranked	11937 citing authors

#	Article	IF	Citations
1	¹³¹I-GD2-ch14.18 Scintigraphy to Evaluate Option for Radioimmunotherapy in Patients with Advanced Tumors. Journal of Nuclear Medicine, 2022, 63, 205-211.	5.0	8
2	¹⁷⁷Lu-Prostate-Specific Membrane Antigen Ligand After ²²³Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience. Journal of Nuclear Medicine, 2022, 63, 410-414.	5.0	19
3	Impact of ¹⁸F-FET PET/MRI on Clinical Management of Brain Tumor Patients. Journal of Nuclear Medicine, 2022, 63, 522-527.	5.0	19
4	Hybrid Cardiac Magnetic Resonance/Fluorodeoxyglucose Positron Emission Tomography to Differentiate Active From Chronic Cardiac Sarcoidosis. JACC: Cardiovascular Imaging, 2022, 15, 445-456.	5.3	33
5	Dose escalation to hypoxic subvolumes in head and neck cancer: A randomized phase II study using dynamic [18F]FMISO PET/CT. Radiotherapy and Oncology, 2022, 171, 30-36.	0.6	22
6	Abstract LB058: Imaging of CD8+ cytotoxic T-cells by Zr-89-Df-IAB22M2C PET/MRI: First clinical experience in patients with metastatic cancer. Cancer Research, 2022, 82, LB058-LB058.	0.9	0
7	Prostate-specific Membrane Antigen Positron Emission Tomographyâ€“detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation. European Urology Focus, 2021, 7, 309-316.	3.1	34
8	Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12197.	2.4	4
9	Impact of PET/CT on management of patients with esophageal cancer â€“ results from a PET/CT registry study. European Journal of Radiology, 2021, 136, 109524.	2.6	3
10	Combining 68Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter Study. Frontiers in Oncology, 2021, 11, 640467.	2.8	11
11	Central Insulin Modulates Dopamine Signaling in the Human Striatum. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2949-2961.	3.6	24
12	18F-Fluoride PET/CT Imaging of Medication-Related Osteonecrosis of the Jaw in Conservative Treatmentâ€”A Case Report. Frontiers in Oncology, 2021, 11, 700397.	2.8	1
13	Value of 18F-PSMA-PET/MRI for Assessment of Recurring Ranula. Diagnostics, 2021, 11, 1462.	2.6	0
14	Machine learning identifies stroke features between species. Theranostics, 2021, 11, 3017-3034.	10.0	12
15	Impact of ¹⁸F-FDG-PET/CT on Clinical Management in Patients with Cholangiocellular Carcinoma. BJR|Open, 2021, 3, 20210008.	0.6	5
16	Lymph Node Staging with a Combined Protocol of ¹⁸F-FDG PET/MRI and Sentinel Node SPECT/CT: A Prospective Study in Patients with FIGO I/II Cervical Carcinoma. Journal of Nuclear Medicine, 2021, 62, 1062-1067.	5.0	6
17	An IgGâ€based bispecific antibody for improved dual targeting in PSMAâ€positive cancer. EMBO Molecular Medicine, 2021, 13, e11902.	6.9	28
18	The Prognostic Value of Quantitative Bone SPECT/CT Before 223Ra Treatment in Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine, 2021, 62, 48-54.	5.0	15

#	Article	IF	Citations
19	⁶⁸Ga-PSMA-PET/CT-directed IGRT/SBRT for oligometastases of recurrent prostate cancer after initial surgery. Acta OncolÃ³gica, 2020, 59, 149-156.	1.8	9
20	Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive in vivo ¹⁸F-FDG-PET. Theranostics, 2020, 10, 925-937.	10.0	46
21	Simultaneous whole-body PET/MRI with integrated multiparametric MRI for primary staging of high-risk prostate cancer. World Journal of Urology, 2020, 38, 2513-2521.	2.2	17
22	Real-space navigation testing differentiates between amyloid-positive and -negative aMCI. Neurology, 2020, 94, e861-e873.	1.1	24
23	Impact of PET/CT on clinical management in patients with cancer of unknown primaryâ€"a PET/CT registry study. European Radiology, 2020, 30, 1325-1333.	4.5	17
24	CT texture analysis compared to Positron Emission Tomography (PET) and mutational status in resected melanoma metastases. European Journal of Radiology, 2020, 131, 109242.	2.6	1
25	Comparison of patient stratification by computed tomography radiomics and hypoxia positron emission tomography in head-and-neck cancer radiotherapy. Physics and Imaging in Radiation Oncology, 2020, 15, 52-59.	2.9	2
26	Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. NeuroImage: Clinical, 2020, 28, 102491.	2.7	17
27	Joint Imaging Platform for Federated Clinical Data Analytics. JCO Clinical Cancer Informatics, 2020, 4, 1027-1038.	2.1	39
28	Is there a link between very early changes of primary and secondary lymphoid organs in ¹⁸F-FDG-PET/MRI and treatment response to checkpoint inhibitor therapy?. , 2020, 8, e000656.		21
29	Influence of 99m-Tc-Nanocolloid Activity Concentration on Sentinel Lymph Node Detection in Endometrial Cancer: A Quantitative SPECT/CT Study. Diagnostics, 2020, 10, 700.	2.6	5
30	Determinants of activity of brown adipose tissue in lymphoma patients. Scientific Reports, 2020, 10, 21802.	3.3	5
31	Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [68Ga]PSMA-PET-guided metastasis-directed therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2328-2338.	6.4	13
32	Influence of 18F-FDG PET/CT on clinical management and outcome in patients with advanced melanoma not primarily selected for surgery based on a linked evidence approach. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2313-2321.	6.4	5
33	PET/MRI and genetic intrapatient heterogeneity in head and neck cancers. Strahlentherapie Und Onkologie, 2020, 196, 542-551.	2.0	8
34	Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial. Lancet Oncology, The, 2020, 21, 581-592.	10.7	121
35	Clinical and prognostic value of tumor volumetric parameters in melanoma patients undergoing 18F-FDG-PET/CT: a comparison with serologic markers of tumor burden and inflammation. Cancer Imaging, 2020, 20, 44.	2.8	13
36	Influence of localization of PSMA-positive oligo-metastases on efficacy of metastasis-directed external-beam radiotherapyâ€"a multicenter retrospective study. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1852-1863.	6.4	16

#	Article	IF	Citations
37	Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy. BMC Cancer, 2020, 20, 362.	2.6	20
38	Independent attenuation correction of whole body [18F]FDG-PET using a deep learning approach with Generative Adversarial Networks. EJNMMI Research, 2020, 10, 53.	2.5	44
39	Correlation of C-arm CT acquired parenchymal blood volume (PBV) with 99mTc-macroaggregated albumin (MAA) SPECT/CT for radioembolization work-up. PLoS ONE, 2020, 15, e0244235.	2.5	2
40	Title is missing!. , 2020, 15, e0244235.		0
41	Title is missing!. , 2020, 15, e0244235.		0
42	Title is missing!. , 2020, 15, e0244235.		0
43	Title is missing!. , 2020, 15, e0244235.		0
44	Dynamic 18F-FET PET is a powerful imaging biomarker in gadolinium-negative gliomas. Neuro-Oncology, 2019, 21, 274-284.	1.2	30
45	Controls-based denoising, a new approach for medical image analysis, improves prediction of conversion to Alzheimerâ€™s disease with FDG-PET. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2370-2379.	6.4	8
46	Report of first recurrent glioma patients examined with PET-MRI prior to re-irradiation. PLoS ONE, 2019, 14, e0216111.	2.5	7
47	Automated Definition of Skeletal Disease Burden in Metastatic Prostate Carcinoma: A 3D Analysis of SPECT/CT Images. Cancers, 2019, 11, 869.	3.7	1
48	Two decades of SPECT/CT â€“ the coming of age of a technology: An updated review of literature evidence. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1990-2012.	6.4	139
49	A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer. , 2019, 7, 307.		39
50	Prospective Evaluation of a Tumor Control Probability Model Based on Dynamic ¹⁸F-FMISO PET for Head and Neck Cancer Radiotherapy. Journal of Nuclear Medicine, 2019, 60, 1698-1704.	5.0	37
51	Intention-to-Treat Analysis of ⁶⁸Ga-PSMA and ¹¹C-Choline PET/CT Versus CT for Prostate Cancer Recurrence After Surgery. Journal of Nuclear Medicine, 2019, 60, 1359-1365.	5.0	29
52	Impact of diverse chemotherapeutic agents and external factors on activation of brown adipose tissue in a large patient collective. Scientific Reports, 2019, 9, 1901.	3.3	7
53	Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 776-787.	6.4	32
54	Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in) Tj ETQq0 0 0 rgBT /Overlock 10 prior use of chemotherapy in routine clinical practice. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1102-1110.	6.4	35

#	Article	IF	Citations
55	Imaging and diagnostic advances for intracranial meningiomas. Neuro-Oncology, 2019, 21, i44-i61.	1.2	100
56	Value of CT iterative metal artifact reduction in PET/CTâ€"clinical evaluation in 100 patients. British Journal of Radiology, 2019, 92, 20180756.	2.2	12
57	Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 540-557.	6.4	348
58	Practice-based evidence for the clinical benefit of PET/CTâ€"results of the first oncologic PET/CT registry in Germany. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 54-64.	6.4	30
59	Transitioning to whole-body SPECT/CT in prostate cancer staging: aÂnew concept for a better imaging workflow. Nuklearmedizin - NuclearMedicine, 2019, 58, 451-459.	0.7	1
60	Independent brain F-FDG PET attenuation correction using a deep learning approach with Generative Adversarial Networks. Hellenic Journal of Nuclear Medicine, 2019, 22, 179-186.	0.3	17
61	Comprehensive metabolic and morphologic disease characterization in systemic sclerosis: initial results using combined positron emission tomography and magnetic resonance imaging. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 207-215.	0.7	2
62	1798-P: Insulin Modulates Dopaminergic Tone in the Human Brainâ€"A Combined PET/MRI Study. Diabetes, 2019, 68, .	0.6	0
63	Abstract 1146: [18F]FPyGal: A novel ÃŸ-galactosidase specific PET tracer forin vivoimaging of tumor senescence. , 2019, , .		15
64	Glioma grading by dynamic susceptibility contrast perfusion and 11C-methionine positron emission tomography using different regions of interest. Neuroradiology, 2018, 60, 381-389.	2.2	12
65	Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. Lancet Neurology, The, 2018, 17, 241-250.	10.2	383
66	A Prospective Study of Quantitative SPECT/CT for Evaluation of Lung Shunt Fraction Before SIRT of Liver Tumors. Journal of Nuclear Medicine, 2018, 59, 1366-1372.	5.0	37
67	Imaging giant cell arteritis and Aortitis in contrast enhanced 18F-FDG PET/CT: Which imaging score correlates best with laboratory inflammation markers?. European Journal of Radiology, 2018, 99, 94-102.	2.6	18
68	Hybrid cardiac imaging using PET/MRI: a joint position statement by the European Society of Cardiovascular Radiology (ESCR) and the European Association of Nuclear Medicine (EANM). European Radiology, 2018, 28, 4086-4101.	4.5	80
69	Hybrid cardiac imaging using PET/MRI: a joint position statement by the European Society of Cardiovascular Radiology (ESCR) and the European Association of Nuclear Medicine (EANM). European Journal of Hybrid Imaging, 2018, 2, .	1.5	6
70	Voxel-wise correlation of functional imaging parameters in HNSCC patients receiving PET/MRI in an irradiation setup. Strahlentherapie Und Onkologie, 2018, 194, 719-726.	2.0	9
71	Clinical use of cardiac PET/MRI: current state-of-the-art and potential future applications. Japanese Journal of Radiology, 2018, 36, 313-323.	2.4	24
72	18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 95-101.	6.4	46

#	Article	IF	Citations
73	Correlation of Brown Adipose Tissue with Other Body Fat Compartments and Patient Characteristics. Academic Radiology, 2018, 25, 102-110.	2.5	57
74	Characterization of Diffuse Gliomas With Histone H3-G34 Mutation by MRI and Dynamic 18F-FET PET. Clinical Nuclear Medicine, 2018, 43, 895-898.	1.3	33
75	Ictal SPECT reveals different epileptogenic zones in frontal lobe epilepsy. Epileptic Disorders, 2018, 20, 447-450.	1.3	0
76	MNGI-11. LONGITUDINAL GENOMIC ANALYSIS OF SPORADIC MENINGIOMAS WITH MULTIPLE RECURRENCES. Neuro-Oncology, 2018, 20, vi150-vi150.	1.2	0
77	Prediction of Non-sentinel Lymph Node Metastases After Positive Sentinel Lymph Nodes Using Nomograms. Anticancer Research, 2018, 38, 4047-4056.	1.1	5
78	Fast non-enhanced abdominal examination protocols in PET/MRI for patients with neuroendocrine tumors (NET): comparison to multiphase contrast-enhanced PET/CT. Radiologia Medica, 2018, 123, 860-870.	7.7	26
79	Hypermetabolism in the cerebellum and brainstem and cortical hypometabolism are independently associated with cognitive impairment in Parkinsonâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2387-2395.	6.4	23
80	Assessment of image quality of a radiotherapy-specific hardware solution for PET/MRI in head and neck cancer patients. Radiotherapy and Oncology, 2018, 128, 485-491.	0.6	32
81	Assessment of Skeletal Tumor Load in Metastasized Castration-Resistant Prostate Cancer Patients: A Review of Available Methods and an Overview on Future Perspectives. Bioengineering, 2018, 5, 58.	3.5	3
82	Computed diffusion weighted imaging (cDWI) and voxelwise-computed diffusion weighted imaging (vcDWI) for oncologic liver imaging: A pilot study. European Journal of Radiology Open, 2018, 5, 108-113.	1.6	1
83	Abstract 3034:18F-FDG-positron emission tomography (PET)/CT enables the identification of checkpoint inhibitor immunotherapy (CIT) responders by determination of CIT-induced metabolic changes in secondary lymphatic organs. , 2018, , .		0
84	Abstract 658: Translational theranostic imaging of lymphoma using radiolabeled Î±CD19-antibodies. , 2018, , .		0
85	Abstract LB-369: In vivo imaging of tumor senescence with a novel beta-galactosidase specific PET tracer. Cancer Research, 2018, 78, LB-369-LB-369.	0.9	3
86	Prognostic value of dynamic hypoxia PET in head and neck cancer: Results from a planned interim analysis of a randomized phase II hypoxia-image guided dose escalation trial. Radiotherapy and Oncology, 2017, 124, 526-532.	0.6	107
87	Simulation of Tracer Dose Reduction in 18F-FDG PET/MRI: Effects on Oncologic Reading, Image Quality, and Artifacts. Journal of Nuclear Medicine, 2017, 58, 1699-1705.	5.0	22
88	Sentinel lymph node mapping using SPECT/CT and gamma probe in endometrial cancer: an analysis of parameters affecting detection rate. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1511-1519.	6.4	18
89	Comparison of DCE-MRI kinetic parameters and FMISO-PET uptake parameters in head and neck cancer patients. Medical Physics, 2017, 44, 2358-2368.	3.0	27
90	Impact of 18F-FDG-PET/CT on surgical management in patients with advanced melanoma: an outcome based analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1312-1318.	6.4	23

#	Article	IF	Citations
91	Pathological ponto-cerebello-thalamo-cortical activations in primary orthostatic tremor during lying and stance. Brain, 2017, 140, 83-97.	7.6	43
92	Distortion correction of diffusion-weighted magnetic resonance imaging of the head and neck in radiotherapy position. Acta OncolÃ³gica, 2017, 56, 1659-1663.	1.8	12
93	Overlap of highly FDG-avid and FMISO hypoxic tumor subvolumes in patients with head and neck cancer. Acta OncolÃ³gica, 2017, 56, 1577-1582.	1.8	20
94	Geometric analysis of loco-regional recurrences in relation to pre-treatment hypoxia in patients with head and neck cancer. Acta OncolÃ³gica, 2017, 56, 1571-1576.	1.8	23
95	Pancreatic Ductal Adenocarcinoma With High Radiotracer Uptake in 68Gaâ€“Prostate-Specific Membrane Antigen PET/CT. Clinical Nuclear Medicine, 2017, 42, 717-718.	1.3	7
96	Improving CT-Based PET Attenuation Correction in the Vicinity of Metal Implants by an Iterative Metal Artifact Reduction Algorithm of CT Data and Its Comparison to Dual-Energyâ€“Based Strategies. Investigative Radiology, 2017, 52, 61-65.	6.2	30
97	Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 92-101.	6.4	237
98	Low Î¼-Opioid Receptor Status in Alcohol Dependence Identified by Combined Positron Emission Tomography and Post-Mortem Brain Analysis. Neuropsychopharmacology, 2017, 42, 606-614.	5.4	51
99	In Vivo Imaging of Glial Activation after Unilateral Labyrinthectomy in the Rat: A [18F]GE180-PET Study. Frontiers in Neurology, 2017, 8, 665.	2.4	15
100	Tumor Burden and Intraosseous Metabolic Activity as Predictors of Bone Marrow Failure during Radioisotope Therapy in Metastasized Prostate Cancer Patients. BioMed Research International, 2017, 2017, 1-10.	1.9	12
101	SUV-quantification of physiological lung tissue in an integrated PET/MR-system: Impact of lung density and bone tissue. PLoS ONE, 2017, 12, e0177856.	2.5	10
102	Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy. Oncotarget, 2017, 8, 44131-44140.	1.8	16
103	Comparison of Positron Emission Tomography Quantification Using Magnetic Resonanceâ€“ and Computed Tomographyâ€“Based Attenuation Correction in Physiological Tissues and Lesions. Investigative Radiology, 2016, 51, 66-71.	6.2	21
104	Pediatric Oncologic Imaging: A Key Application of Combined PET/MRI. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2016, 188, 359-364.	1.3	20
105	Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro-Oncology, 2016, 18, 1199-1208.	1.2	566
106	Defining optimal tracer activities in pediatric oncologic whole-body 18F-FDG-PET/MRI. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2283-2289.	6.4	42
107	Decoding Intratumoral Heterogeneity of Breast Cancer by Multiparametric In Vivo Imaging: A Translational Study. Cancer Research, 2016, 76, 5512-5522.	0.9	33
108	Occupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson's disease patients. NeuroImage: Clinical, 2016, 12, 41-46.	2.7	14

#	Article	IF	Citations
109	Pericervical Injection of 99mTc-Nanocolloid Is Superior to Peritumoral Injection for Sentinel Lymph Node Detection of Endometrial Cancer in SPECT/CT. Clinical Nuclear Medicine, 2016, 41, 927-932.	1.3	15
110	Assessment of the parenchymal blood volume by C-arm computed tomography for radioembolization dosimetry. European Journal of Radiology, 2016, 85, 1525-1531.	2.6	4
111	Nicotineâ€“dopamine-transporter interactions during reward-based decision making. European Neuropsychopharmacology, 2016, 26, 938-947.	0.7	4
112	Sequential [18F]FDG ÂµPET whole-brain imaging of central vestibular compensation: a model of deafferentation-induced brain plasticity. Brain Structure and Function, 2016, 221, 159-170.	2.3	49
113	CT imaging of bone and bone marrow infiltration in malignant melanomaâ€”Challenges and limitations for clinical staging in comparison to 18FDG-PET/CT. European Journal of Radiology, 2016, 85, 732-738.	2.6	43
114	Implementation of the European multicentre database of healthy controls for [123I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1315-1322.	6.4	29
115	Early static 18F-FET-PET scans have a higher accuracy for glioma grading than the standard 20â€“40 min scans. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1105-1114.	6.4	88
116	Influence of 18F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 482-488.	6.4	37
117	Anisotropy of Human Horizontal and Vertical Navigation in Real Space: Behavioral and PET Correlates. Cerebral Cortex, 2016, 26, 4392-4404.	2.9	42
118	Assessment of metastatic colorectal cancer with hybrid imaging: comparison of reading performance using different combinations of anatomical and functional imaging techniques in PET/MRI and PET/CT in a short case series. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 123-132.	6.4	81
119	Derivation of a respiration trigger signal in small animal list-mode PET based on respiration-induced variations of the ECG signal. Journal of Nuclear Cardiology, 2016, 23, 73-83.	2.1	3
120	Towards tracer dose reduction in PET studies: Simulation of dose reduction by retrospective randomized undersampling of list-mode data. Hellenic Journal of Nuclear Medicine, 2016, 19, 15-8.	0.3	25
121	Dynamic ¹⁸<scp>Fâ€FET PET</scp> in suspected <scp>WHO</scp> grade II gliomas defines distinct biological subgroups with different clinical courses. International Journal of Cancer, 2015, 136, 2132-2145.	5.1	68
122	Segmentation-Based Attenuation Correction in Positron Emission Tomography/Magnetic Resonance. Investigative Radiology, 2015, 50, 339-346.	6.2	38
123	Multiparametric analysis of bone marrow in cancer patients using simultaneous PET/MR imaging: Correlation of fat fraction, diffusivity, metabolic activity, and anthropometric data. Journal of Magnetic Resonance Imaging, 2015, 42, 1048-1056.	3.4	28
124	Combined unsupervisedâ€“supervised classification of multiparametric PET/MRI data: application to prostate cancer. NMR in Biomedicine, 2015, 28, 914-922.	2.8	24
125	N-Acetyl-L-Leucine Accelerates Vestibular Compensation after Unilateral Labyrinthectomy by Action in the Cerebellum and Thalamus. PLoS ONE, 2015, 10, e0120891.	2.5	60
126	Methylphenidate Effects on Brain Activity as a Function of SLC6A3 Genotype and Striatal Dopamine Transporter Availability. Neuropsychopharmacology, 2015, 40, 736-745.	5.4	22

#	Article	IF	Citations
127	Biological tumor volume in ¹⁸ FET-PET before radiochemotherapy correlates with survival in GBM. Neurology, 2015, 84, 710-719.	1.1	144
128	Altered serotonin and dopamine transporter availabilities in brain of depressed patients upon treatment with escitalopram: A [123I]Î²-CIT SPECT study. European Neuropsychopharmacology, 2015, 25, 873-881.	0.7	26
129	Prognostic Significance of Dynamic ¹⁸F-FET PET in Newly Diagnosed Astrocytic High-Grade Glioma. Journal of Nuclear Medicine, 2015, 56, 9-15.	5.0	144
130	Combined PET/MRI: Multi-modality Multi-parametric Imaging Is Here. Molecular Imaging and Biology, 2015, 17, 595-608.	2.6	56
131	Robustness of quantitative hypoxia PET image analysis for predicting local tumor control. Acta OncolÃ³gica, 2015, 54, 1364-1369.	1.8	22
132	Hybrid MR-PET in Neuroimaging. Clinical Neuroradiology, 2015, 25, 275-281.	1.9	4
133	PET/MR in Oncology. Current Radiology Reports, 2015, 3, 1.	1.4	0
134	Is the standard uptake value (SUV) appropriate for quantification in clinical PET imaging? â€“ Variability induced by different SUV measurements and varying reconstruction methods. European Journal of Radiology, 2015, 84, 158-162.	2.6	42
135	In vivo visualization of prostate-specific membrane antigen in glioblastoma. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 170-171.	6.4	85
136	Determination of Split Renal Function Using Dynamic CT-Angiography: Preliminary Results. PLoS ONE, 2014, 9, e91774.	2.5	18
137	Assessment of cerebral dopamine D 2 / 3 -receptors in patients with bilateral vestibular failure. Journal of Vestibular Research: Equilibrium and Orientation, 2014, 24, 403-413.	2.0	12
138	Diffuse leukoencephalopathy with spheroids: Biopsy findings and a novel mutation. Clinical Neurology and Neurosurgery, 2014, 122, 113-115.	1.4	10
139	Radius dependence of FP-CIT quantification: a Monte Carlo-based simulation study. Annals of Nuclear Medicine, 2014, 28, 103-111.	2.2	13
140	Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option. Journal of Neuro-Oncology, 2014, 117, 337-345.	2.9	66
141	Molecular stereotactic biopsy technique improves diagnostic accuracy and enables personalized treatment strategies in glioma patients. Acta Neurochirurgica, 2014, 156, 1427-1440.	1.7	51
142	Dynamic ¹⁸F-FET PET in Newly Diagnosed Astrocytic Low-Grade Glioma Identifies High-Risk Patients. Journal of Nuclear Medicine, 2014, 55, 198-203.	5.0	123
143	Extrastriatal binding of [123I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1938-1946.	6.4	60
144	The mixed blessing of treating symptoms in acute vestibular failure â€” Evidence from a 4-aminopyridine experiment. Experimental Neurology, 2014, 261, 638-645.	4.1	34

#	Article	IF	Citations
145	4-Aminopyridine suppresses positional nystagmus caused by cerebellar vermis lesion. Journal of Neurology, 2013, 260, 321-323.	3.6	32
146	Effects of acute detoxification of the herbal blend â€˜Spice Goldâ€™ on dopamine D2/3 receptor availability: A [18F]fallypride PET study. European Neuropsychopharmacology, 2013, 23, 1606-1610.	0.7	31
147	Impulsivity is related to striatal dopamine transporter availability in healthy males. Psychiatry Research - Neuroimaging, 2013, 211, 251-256.	1.8	33
148	[18F]-fluoro-ethyl-l-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. Neuro-Oncology, 2013, 15, 341-351.	1.2	192
149	Response to "Reply to [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma" by Hutterer et al.. Neuro-Oncology, 2013, 15, 814-815.	1.2	7
150	3D-OSEM and FP-CIT SPECT quantification. Nuclear Medicine Communications, 2013, 34, 971-977.	1.1	2
151	Functional disturbance of the locomotor network in progressive supranuclear palsy. Neurology, 2013, 80, 634-641.	1.1	69
152	Erroneous cardiac ECG-gated PET list-mode trigger events can be retrospectively identified and replaced by an offline reprocessing approach: first results in rodents. Physics in Medicine and Biology, 2013, 58, 7937-7959.	3.0	12
153	Surrogate markers for cerebral blood flow correlate with [¹⁸F]â€fallypride binding potential at dopamine D_{2/3} receptors in human striatum. Synapse, 2013, 67, 199-203.	1.2	21
154	[¹⁸ F]Fluoroethyltyrosineâ€“Positron Emission Tomography-Based Therapy Monitoring after Stereotactic Iodine-125 Brachytherapy in Patients with Recurrent High-Grade Glioma. Molecular Imaging, 2013, 12, 7290.2012.00027.	1.4	36
155	[18F]fluoroethyltyrosine-positron emission tomography-based therapy monitoring after stereotactic iodine-125 brachytherapy in patients with recurrent high-grade glioma. Molecular Imaging, 2013, 12, 137-47.	1.4	24
156	Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [18F]FET-PET imaging in intracranial WHO grade II and III gliomas. Neuro-Oncology, 2012, 14, 1473-1480.	1.2	91
157	Intramedullary Pilomyxoid Astrocytoma with Intracerebral Metastasis Exhibiting Oligoden-Droglioma-Like Features. Rare Tumors, 2012, 4, 92-95.	0.6	5
158	Striatal Dopamine Transporter Binding in Adults With ADHD. American Journal of Psychiatry, 2012, 169, 665-665.	7.2	3
159	Re-irradiation in recurrent malignant glioma: prognostic value of [18F]FETâ€“PET. Journal of Neuro-Oncology, 2012, 110, 389-395.	2.9	34
160	Irradiation and Bevacizumab in High-Grade Glioma Retreatment Settings. International Journal of Radiation Oncology Biology Physics, 2012, 82, 67-76.	0.8	119
161	FET-PET assessed recurrence pattern after radio-chemotherapy in newly diagnosed patients with glioblastoma is influenced by MGMT methylation status. Radiotherapy and Oncology, 2012, 104, 78-82.	0.6	50
162	Evaluation of contrast medium enhancement and [18F]-FDG uptake of liver metastasis in PET/CT prior to therapy. European Journal of Radiology, 2012, 81, 652-657.	2.6	1

#	Article	IF	Citations
163	Compensation for cranial spillâ€in into the cerebellum improves quantitation of striatal dopamine D_{2/3} receptors in rats with prolonged [¹⁸F]â€DMFP infusions. Synapse, 2012, 66, 705-713.	1.2	9
164	MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET?. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1021-1029.	6.4	160
165	Dual-isotope SPECT imaging of striatal dopamine: a comparative study between never-treated and haloperidol-treated first-episode schizophrenic patients. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 183-191.	3.2	13
166	[¹⁸F]fallypride PET measurement of striatal and extrastriatal dopamine D_{2/3} receptor availability in recently abstinent alcoholics. Addiction Biology, 2012, 17, 490-503.	2.6	50
167	Where in-vivo imaging meets cytoarchitectonics: The relationship between cortical thickness and neuronal density measured with high-resolution [18F]flumazenil-PET. NeuroImage, 2011, 56, 951-960.	4.2	113
168	Bilateral temporal lobe epilepsy confirmed with intracranial EEG in chorea-acanthocytosis. Seizure: the Journal of the British Epilepsy Association, 2011, 20, 340-342.	2.0	18
169	FETâ€“PET for malignant glioma treatment planning. Radiotherapy and Oncology, 2011, 99, 44-48.	0.6	125
170	Effects of a 6-Month Cognitive Intervention Program on Brain Metabolism in Amnestic Mild Cognitive Impairment and Mild Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 25, 695-706.	2.6	30
171	PET/CT in malignant melanoma: contrast-enhanced CT versus plain low-dose CT. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 822-831.	6.4	47
172	Postural imbalance and falls in PSP correlate with functional pathology of the thalamus. Neurology, 2011, 77, 101-109.	1.1	84
173	Molecular imaging of gliomas with PET: Opportunities and limitations. Neuro-Oncology, 2011, 13, 806-819.	1.2	225
174	Hot spots in dynamic18FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro-Oncology, 2011, 13, 307-316.	1.2	215
175	Myocardial Perfusion Imaging is Feasible for Infarct Size Quantification in Mice Using a Clinical Single-photon Emission Computed Tomography System Equipped with Pinhole Collimators. Molecular Imaging and Biology, 2010, 12, 427-434.	2.6	23
176	FDG-PET mapping the brain substrates of visuo-constructive processing in AlzheimerÂ´s disease. Journal of Psychiatric Research, 2010, 44, 462-469.	3.1	40
177	Imaging of Pâ€glycoproteinâ€“mediated pharmacoresistance in the hippocampus: Proofâ€ofâ€concept in a chronic rat model of temporal lobe epilepsy. Epilepsia, 2010, 51, 1780-1790.	5.1	45
178	In Vivo Imaging of Macrophage Activity in the Coronary Arteries Using ⁶⁸Ga-DOTATATE PET/CT: Correlation with Coronary Calcium Burden and Risk Factors. Journal of Nuclear Medicine, 2010, 51, 193-197.	5.0	137
179	The Value of the Dopamine D_{2/3} Receptor Ligand ¹⁸F-Desmethoxyfallypride for the Differentiation of Idiopathic and Nonidiopathic Parkinsonian Syndromes. Journal of Nuclear Medicine, 2010, 51, 581-587.	5.0	51
180	Functional Representation of Olfactory Impairment in Early Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 22, 581-591.	2.6	66

#	Article	IF	Citations
181	Uptake and binding of the serotonin 5-HT1A antagonist [18F]-MPPF in brain of rats: Effects of the novel P-glycoprotein inhibitor tariquidar. NeuroImage, 2010, 49, 1406-1415.	4.2	47
182	Real versus imagined locomotion: A [18F]-FDG PET-fMRI comparison. NeuroImage, 2010, 50, 1589-1598.	4.2	342
183	Increase of striatal dopamine transmission in first episode drug-naive schizophrenic patients as demonstrated by [123I]IBZM SPECT. Psychiatry Research - Neuroimaging, 2009, 173, 183-189.	1.8	23
184	Improved work-up procedure for the production of [18F]flumazenil and first results of its use with a high-resolution research tomograph in human stroke. Nuclear Medicine and Biology, 2009, 36, 721-727.	0.6	35
185	PET and SPECT in epilepsy: A critical review. Epilepsy and Behavior, 2009, 15, 50-55.	1.7	171
186	Ictal SPECT in Sturge-Weber syndrome. Epilepsy Research, 2008, 78, 240-243.	1.6	11
187	Dual-isotope SPECT imaging of striatal dopamine: First episode, drug naÃ¯ve schizophrenic patients. Schizophrenia Research, 2008, 101, 133-141.	2.0	43
188	Hepatic Yttrium-90 Radioembolization of Chemotherapy-refractory Colorectal Cancer Liver Metastases. Journal of Vascular and Interventional Radiology, 2008, 19, 1187-1195.	0.5	130
189	Radioembolization in Patients with Hepatic Metastases from Breast Cancer. Journal of Vascular and Interventional Radiology, 2008, 19, 683-690.	0.5	103
190	Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 767-773.	1.9	234
191	Striatal D2/D3 Receptor Occupancy, Clinical Response and Side Effects with Amisulpride: An Iodine-123-Iodobenzamide SPET Study. Pharmacopsychiatry, 2008, 41, 169-175.	3.3	46
192	Quantitative assessment of cardiac allograft vasculopathy by real-time myocardial contrast echocardiography: A comparison with conventional echocardiographic analyses and [Tc99m]-sestamibi SPECT. European Journal of Echocardiography, 2007, 9, 494-500.	2.3	25
193	F-18-Fluoro-2-Deoxyglucose Positron Emission Tomography/Computed Tomography in the Follow-up of Breast Cancer With Elevated Levels of Tumor Markers. Journal of Computer Assisted Tomography, 2007, 31, 629-634.	0.9	38
194	Effects of peripheral vascular intervention on ischemia-modified albumin. Coronary Artery Disease, 2007, 18, 375-379.	0.7	15
195	Value of 99mTc-TRODAT-1 SPECT to predict clinical response to methylphenidate treatment in adults with attention deficit hyperactivity disorder. Nuclear Medicine Communications, 2006, 27, 733-737.	1.1	63
196	Clinical validation of the gated blood pool SPECT QBSÂ® processing software in congestive heart failure patients: correlation with MUGA, first-pass RNV and 2D-echocardiography. International Journal of Cardiovascular Imaging, 2006, 22, 407-416.	1.5	33
197	Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drugâ€“naive schizophrenic patients. European Archives of Psychiatry and Clinical Neuroscience, 2006, 256, 115-121.	3.2	46
198	Value of PET/CT versus PET and CT performed as separate investigations in patients with Hodgkinâ€™s disease and non-Hodgkinâ€™s lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 1417-1425.	6.4	85

#	Article	IF	Citations
199	Striatal dopamine transporter availability and DAT-1 gene in adults with ADHD: no higher DAT availability in patients with homozygosity for the 10-repeat allele. World Journal of Biological Psychiatry, 2006, 7, 152-157.	2.6	42
200	ADHD in adolescence and adulthood, with a special focus on the dopamine transporter and nicotine. Dialogues in Clinical Neuroscience, 2006, 8, 29-36.	3.7	26
201	Influence of striatal dopamine transporter availability on the response to methylphenidate in adult patients with ADHD. European Archives of Psychiatry and Clinical Neuroscience, 2005, 255, 428-431.	3.2	72
202	The striatal dopamine transporter in first-episode, drug-naive schizophrenic patients: evaluation by the new SPECT-ligand[99mTc]TRODAT-1. Journal of Psychopharmacology, 2005, 19, 488-493.	4.0	42
203	D2 receptor occupancy during high- and low-dose therapy with the atypical antipsychotic amisulpride: a 123I-iodobenzamide SPECT study. Journal of Nuclear Medicine, 2005, 46, 1028-33.	5.0	30
204	The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder. Neuroscience and Biobehavioral Reviews, 2003, 27, 605-613.	6.1	168